ATE386529T1 - Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen - Google Patents

Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen

Info

Publication number
ATE386529T1
ATE386529T1 AT03768023T AT03768023T ATE386529T1 AT E386529 T1 ATE386529 T1 AT E386529T1 AT 03768023 T AT03768023 T AT 03768023T AT 03768023 T AT03768023 T AT 03768023T AT E386529 T1 ATE386529 T1 AT E386529T1
Authority
AT
Austria
Prior art keywords
sub
sup
alkyl
heteroaryl
aryl
Prior art date
Application number
AT03768023T
Other languages
English (en)
Inventor
Shudong Wang
Christopher Meades
Gavin Wood
Kenneth Duncan
Daniella Zheleva
Peter Fischer
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE386529T1 publication Critical patent/ATE386529T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
AT03768023T 2002-12-19 2003-12-18 Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen ATE386529T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229581.4A GB0229581D0 (en) 2002-12-19 2002-12-19 Use

Publications (1)

Publication Number Publication Date
ATE386529T1 true ATE386529T1 (de) 2008-03-15

Family

ID=9949983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03768023T ATE386529T1 (de) 2002-12-19 2003-12-18 Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen

Country Status (14)

Country Link
US (1) US20050282843A1 (de)
EP (1) EP1572211B1 (de)
JP (1) JP2006515588A (de)
CN (1) CN100425239C (de)
AT (1) ATE386529T1 (de)
AU (1) AU2003292444A1 (de)
BR (1) BR0316703A (de)
CA (1) CA2502138A1 (de)
DE (1) DE60319269T2 (de)
ES (1) ES2300617T3 (de)
GB (1) GB0229581D0 (de)
MX (1) MXPA05006515A (de)
NZ (1) NZ539671A (de)
WO (1) WO2004056368A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
US7456190B2 (en) * 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
CA2542880A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
PL1799230T3 (pl) 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych
FR2881742B1 (fr) * 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US8492428B2 (en) 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
CN101321531A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
GB0520955D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102006001161A1 (de) * 2006-01-06 2007-07-12 Qiagen Gmbh Verfahren zum Nachweis von Cytosin-Methylierungen
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
HUE031580T2 (en) 2008-08-15 2017-07-28 Nivalis Therapeutics Inc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
EP2315590B1 (de) 2008-08-15 2012-09-26 N30 Pharmaceuticals, LLC Pyrrolhemmer der s-nitrosoglutathion-reduktase
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
RU2011140238A (ru) 2009-04-15 2013-05-20 Астразенека Аб Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера
US9340511B2 (en) * 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
WO2014199164A1 (en) * 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135699T1 (de) * 1986-01-13 1996-04-15 American Cyanamid Co 4,5,6-substituierte 2-pyrimidinamine
ES2160597T3 (es) * 1992-03-06 2001-11-16 Lica Pharmaceuticals As Tratamiento y profilaxis de enfermedades producidas por parasitos o bacterias.
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6417185B1 (en) * 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AU2001242629B2 (en) * 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
BR0207096A (pt) * 2001-02-20 2004-01-20 Astrazeneca Ab Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
CA2446756C (en) * 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
ATE349443T1 (de) * 2001-09-28 2007-01-15 Cyclacel Ltd N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
CA2533870A1 (en) * 2003-07-30 2005-02-10 Shudong Wang Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
EP1648875A1 (de) * 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidine als kinaseinhibitoren
CA2542880A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
PL1799230T3 (pl) * 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych

Also Published As

Publication number Publication date
CA2502138A1 (en) 2004-07-08
NZ539671A (en) 2007-04-27
WO2004056368A1 (en) 2004-07-08
CN100425239C (zh) 2008-10-15
MXPA05006515A (es) 2005-09-08
AU2003292444A1 (en) 2004-07-14
DE60319269D1 (de) 2008-04-03
BR0316703A (pt) 2005-10-18
EP1572211A1 (de) 2005-09-14
GB0229581D0 (en) 2003-01-22
EP1572211B1 (de) 2008-02-20
US20050282843A1 (en) 2005-12-22
ES2300617T3 (es) 2008-06-16
JP2006515588A (ja) 2006-06-01
CN1720049A (zh) 2006-01-11
DE60319269T2 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
DE60319269D1 (de) Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
ATE300521T1 (de) Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
HUP0100950A2 (hu) Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények
EA200600648A1 (ru) Производные пурина, ингибирующие репликацию вич
RU2009132188A (ru) Режим дозирования ингибиторов комт
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
DK0873319T3 (da) Quinazolinderivater
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
ATE419245T1 (de) Cinnoline verbindungen
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
BR0012157A (pt) Derivado de quinazolina, derivado de pirimidina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para a prevenção ou tratamento de doenças ou condições médicas pela célula t um em animal de sangue quente em necessidade de tal tratamento
RU2010154173A (ru) Режим введения нитрокатехолов
DK1057828T3 (da) Orale trovafloxacin-suspensioner
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
MA27129A1 (fr) Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine.
WO2007120726B1 (en) Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
ATE361749T1 (de) Benzthiazol-3 oxide zur behandlung von proliferativen störungen
CY1109678T1 (el) Νεα παραγωγα 3-φαινυλπροπιονικου οξεος και χρηση αυτων ως συνδετηρες του υποδοχεα ppar-γαμμα
EP1750703A4 (de) Verfahren zur verringerung der gastrointestinalen toxizität durch verabreichung von tegafur

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572211

Country of ref document: EP

REN Ceased due to non-payment of the annual fee